Aradigm lands NIH grant for inhaled, liposomal products

Aradigm Corp. (NSDQ:ARDM) said today that the National Institute of Allergy and Infectious Diseases and the NIH awarded the company a grant to study the treatment of pulmonary non-tuberculous mycobacteria infections with Aradigm’s inhaled liposomal ciprofloxacin products, Linhaliq and Lipoquin. The two-year grant is worth approximately $972,000, according to the Hayward, Calif.-based company. Get the full story at our sister site, Drug Delivery Business News. The post Aradigm lands NIH grant for inhaled, liposomal products appeared first on MassDevice.
Source: Mass Device - Category: Medical Devices Authors: Tags: Drug-Device Combinations Funding Roundup Pharmaceuticals Respiratory Wall Street Beat Aradigm Corp. Source Type: news